Drug class profile · refreshed daily from federal data

Cholinergic Receptor Agonist

2 molecules in this class, $63.2M combined CY2024 Part D spend across 665K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Cholinergic Receptor Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $63.2Mcombined across class
Total Rx claims: 665K232K unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Pilocarpine

Brand: Qlosi · 490K Part D claims (CY24) · 176K beneficiaries · First FDA approval: 2005-10-14

9 generic mfrs 3 plans require PA Discontinued

Low NADAC$0.303

→

Avg plan cost$4.70

Part D spend $32.9M 16× spread, current vs floor

Class share

52%

of class CY24 spend

View profile →

Cevimeline

Brand: CEVIMELINE · 175K Part D claims (CY24) · 56K beneficiaries · First FDA approval: 2013-07-08

8 generic mfrs 0 plans require PA

Low NADAC$0.687

→

Avg plan cost$1.57

Part D spend $30.3M 2× spread, current vs floor

Class share

48%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.